Erlotinib Completed Phase 1 / 2 Trials for Head and Neck Carcinoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment1 / 2
clinicaltrials.gov IdentifierTitleDrugs
NCT00079053Adjuvant Erlotinib After Completing Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
NCT00113347Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)